Here are the comprehensive details of Influx Healthtech Limited IPO:
IPO Dates
| Event | Date |
|---|---|
| Opening Date | June 18, 2025 |
| Closing Date | June 20, 2025 |
| Allotment Finalized | June 23, 2025 |
| Refunds & Shares Credited | June 24, 2025 |
| Listing Date | June 25, 2025 |
IPO Details
| Attribute | Details |
|---|---|
| IPO Type | SME, Book-Built, NSE Emerge |
| Face Value | ₹10 per share |
| Issue Size | 61,00,800 shares |
| Price Band | ₹91 to ₹96 per share |
| Lot Size | 1,200 Shares |
| Offer for Sale | 11,00,400 shares of ₹10 (aggregating up to ₹10.56 Cr) |
| Total Issue Size | 61,00,800 shares (aggregating up to ₹58.57 Cr) |
| Fresh Issue | 50,00,400 shares (aggregating up to ₹48.00 Cr) |
| Listing At | NSE SME |
| Registrar | Skyline Financial Services |
Promoters of Influx Healthtech Limited
Here are the key details about the promoters of Influx Healthtech Limited based on its IPO filings and official records:
Munir Abdul Ganee Chandniwala
- Role: Founder, Promoter, and Managing Director
Background:
- Holds a Bachelor of Pharmacy from the University of Pune (2002), an MBA from Atharva School of Business, Mumbai (2004–2006), and a PhD from Bharatiya Shiksha Parishad, UP (2010).
- Additionally earned a Diploma in Nutrition from Fab Academe, California (2019).
- Over 18–20 years of experience in nutraceuticals, cosmetics, ayurvedic, veterinary, homecare, CDMO and contract manufacturing.
- Registered pharmacist with the Maharashtra State Pharmacy Council.
Shirin Munir Ahmed Chandniwala
- Role: Promoter and Director
- Details: Appointed as Director on 28 September 2020, alongside Munir, as reflected in company records
At a Glance
| Promoter | Role | Key Credentials |
|---|---|---|
| Munir Abdul G. Chandniwala | Founder, MD, Promoter | B.Pharm, MBA, PhD, Nutrition diploma; 18‑20 yrs in CDMO |
| Shirin M. A. Chandniwala | Director, Promoter | Director since Sep 2020; shared promoter status |
GMP of Influx Healthtech Limited IPO
There’s currently no confirmed figure for the Grey Market Premium (GMP) of the Influx Healthtech IPO available in unofficial channels like Telegram or IPO tracking websites. Before the IPO opens (June 18–20, 2025), grey market premiums aren’t consistently published—so any claimed GMP may just be speculative.
Influx Healthtech Limited IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Minimum) | 1 | 1200 | ₹1,15,200 |
| Retail (Maximum) | 1 | 1200 | ₹1,15,200 |
| HNI (Minimum) | 2 | 2,400 | ₹2,30,400 |
Influx Healthtech Limited IPO Promoter Holding
| Description | Holding (approx.) |
|---|---|
| Pre-IPO | 99.85% |
| Post-IPO | 73.53% |
- Before the IPO, the promoters held virtually 100% of the issued share capital—reportedly 99.85%.
- After the IPO, promoter holdings are projected to fall to approximately 73.5%, due to the sale of ~11.0 lakh shares by the promoter (
Offer for Sale).
About Influx Healthtech Limited
Founded in 2002–2003 in Mumbai as a micro plant; evolved into a leading CDMO (Contract Development & Manufacturing Organization) based in Palghar, Maharashtra
Key Directors:
- Shirin Munir Ahmed Chandniwala (Whole-Time Director): B.Com, ~12 years in packaging and third-party manufacturing.
- Abdul Ganee Abdul Rasul Chandniwala (Non‑Exec Director): Diploma in Homeopathic/Biochemic systems; ~21 years pharma experience.
Founder & MD: Dr. Munir Abdul Ganee Chandniwala
- B. Pharm (Pune, 2002), MBA (Mumbai, 2006), PhD (Bharatiya Shiksha Parishad, 2010)
- Diploma in Nutrition (Fab Academe, California, 2019)
- ~22 years in nutraceutical, cosmetic, ayurvedic, and homecare CDMO.
- Registered pharmacist in Maharashtra.
Operations & Capabilities
Facilities:
- Three GMP-, HACCP-, ISO 22000-, Halal- and US FDA-certified plants in Palghar, totaling ~72,000 sq ft.
Product Portfolio:
- Nutraceuticals (capsules, tablets, soft gels, effervescent, gummies)
- Cosmetics (creams, oils, soaps)
- Ayurvedic/herbal formulations
- Veterinary feed supplements
- Homecare products (ODFs, bars, powders)
- APIs and finished dosage forms
Clients include domestic and global brands like Bling Brands, Pursuit of Wellness, Aarkios Health, HSHS Nutraceuticals, Novus Life, Bruder Life, Fredun Pharma, Bigflex Lifescience .
Market Reach & Certifications
- Global footprint: Exports across South America, South & SE Asia; presence in Europe, North America, and the Middle East.
- Quality credentials: WHO-GMP, ISO 22000:2018, ISO 14001:2015, HACCP, Halal, US FDA for cosmetics, and FSSAI certification.
Competitive Strengths
- Comprehensive product range under one roof.
- Multi-certified, export‑ready manufacturing capacity.
- Strong promoter pedigree, with deep sector experience.
- Proven growth track record & profitability.
- R&D capabilities enabling innovation and customization.
Summary
Influx Healthtech is a rapidly growing, well‑certified CDMO catering to global clients across health, wellness, veterinary, and homecare segments. With robust R&D, manufacturing scale, and financial momentum, the IPO aims to propel capacity and market reach further.
Influx Healthtech Limited Financial Information
| Period Ended | 31 Mar 2025 | Mar 31 2024 | 31 Mar 2023 |
| Assets | ₹70.30 Crore | ₹41.10 Crore | ₹28.30 Crore |
| Revenue | ₹104.99 Crore | ₹100.10 Crore | ₹76.07 Crore |
| Profit After Tax | ₹13.37 Crore | ₹11.22 Crore | ₹7.20 Crore |
| Net Worth | ₹36.15 Crore | ₹22.87 Crore | ₹11.65 Crore |
| Reserves and Surplus | ₹18.00 Crore | ₹22.85 Crore | ₹11.63 Crore |
| Total Borrowing | ₹0.22 Crore | ₹0.32 Crore | ₹0.80 Crore |
Key Performance Indicator (KPI)
| KPI | Values |
|---|---|
| ROE | 36.98% |
| ROCE | 49.17% |
| Debt/Equity | 0.01 |
| RoNW | 36.98% |
| PAT Margin | 12.75 |
| Price to Book Value | 7.62 |
Objects of the Issue
Here are the Objects of the Issue (use of IPO proceeds) for Influx Healthtech Limited, as laid out in its Draft Red Herring Prospectus:
1) Capex for Nutraceutical Facility
- ₹21.61 crore to set up a new manufacturing facility dedicated to nutraceuticals.
2) Capex for Veterinary Food Facility
- ₹8.76 crore to fund a new manufacturing plant for veterinary feed supplements.
3) Purchase of Machinery for Homecare & Cosmetic Division
- ₹2.66 crore allocated to machinery and equipment for the homecare and cosmetic product lines.
4) General Corporate Purposes
- Remaining funds to be used for routine business needs and potential strategic opportunities.
Structured Breakdown
| Objective | Amount (₹ crore) |
|---|---|
| Nutraceutical Division – new facility | 21.61 |
| Veterinary Food Division – new facility | 8.76 |
| Homecare & Cosmetic Division – machinery | 2.66 |
| General Corporate Purposes | Remaining balance |
Strengths of Influx Healthtech Limited IPO
1) Robust Growth & Profitability
- Revenue grew ~32% to ₹99.96 cr in FY24, while PAT surged ~56% to ₹11.22 cr.
- Demonstrates strong top-line scaling and improved margins (~11.2% PAT margin in FY24).
2) Diversified and High‑Value Product Portfolio
- Broad coverage across nutraceuticals, cosmetics, veterinary feed, ayurvedic & homecare products.
- Operates unique formats like ice‑candy supplements, ODFs, protein bars, and premixes — showcasing innovation.
3) Well‑Certified Manufacturing Infrastructure
- Three GMP-, HACCP-, ISO 22000 & Halal‑certified plants (~33,500 sq ft) in Palghar, equipped for large commercial batches.
- FDA‑approved cosmetics lines enhance export credibility.
4) Strong Founding Team
- Promoter Munir Chandniwala holds a B.Pharm, MBA, PhD, and nutrition diploma with ~18–22 years of domain experience.
- Leadership adds operational knowledge and industry insight.
5) Clear Growth Capital Utilization
- IPO proceeds earmarked for capacity expansion: ₹21.6 cr (nutraceuticals), ₹8.8 cr (veterinary), ₹2.7 cr (homecare/cosmetics) — well-targeted investments.
Risks of Influx Healthtech Limited IPO
1) Strong Competition & Industry Dynamics
- CDMO space is crowded with well-capitalized players; Influx must maintain innovation and cost advantage.
2) Execution Risk
- Expansion hinges on timely capex execution and efficient integration of new capacities — delays or cost overruns could delay returns.
3) Regulatory & Quality Compliance
- While currently certified, the food, cosmetic, pharmaceutical sectors are highly regulated. Any compliance lapses (e.g. FDA or FSSAI) may impact operations.
4) Client Concentration & Price Pressures
- Heavy dependence on contract-manufacturing implies clients can switch to competitors or negotiate pricing, potentially squeezing margins.
5) SME Listing Challenges
- Listed on NSE Emerge (SME segment), which historically sees lower liquidity and investor interest than mainboard listings—could impact post-listing stock performance.
6) IPO Market Volatility
- SME IPOs are prone to listing day volatility; external factors like interest rates, investor sentiment, and macroeconomic trends may affect listing gains.
Final Take
Influx Healthtech stands out with strong financial momentum, a diversified and innovative product line, and credible manufacturing credentials—boosted by clear, capex-driven growth plans. However, investors should be mindful of execution risks, regulatory dependencies, competitive pressures in the CDMO space, and typical SME listing uncertainties.
Influx Healthtech Limited Contact Details
📍 Registered & Corporate Office Address
109, Ghanshyam Enclave Premises Co‑op Soc, Plot No. 856, Laljipada, New Link Road, Behind Laljipada Police Chowky, Kandivali (West), Mumbai, Maharashtra 400067, India
☎️ Phone Numbers
| Source | Number |
|---|---|
| Zaubee / CPHI-Online | +91 91525 57994 |
| SignalHire | +91 98202 01063 |
| Bajaj Finserv Markets¹ | +91 70459 97809 |
📧 Email Addresses
IPO/Inquiries Email: cs@influxhealthtceh.com
Corporate Email: influxhealthtech@gmail.com
🌐 Website
- Official: influxhealthtech.com
Influx Healthtech Limited IPO Registrar
🧾 Registrar to the Issue
- Maashitla Securities Private Limited
Appointed as the official registrar responsible for processing applications, allotment, refunds, and related IPO activities.
🔧 Registrar Roles & Responsibilities
- Managing application records across investor categories (QIB, NII, Retail).
- Conducting allotment of shares post-IPO closure.
- Handling refunds for unsuccessful applicants.
- Coordinating with exchanges to ensure timely demat credit and IPO finalization.
Eppeltone Engineers Limited IPO 2025 Details: Dates, Lot Size, Price & Review
Patil Automation Limited IPO 2025 Details: Date, Price, GMP & Review
Disclaimer: The content on this website is intended for informational purposes only and should not be interpreted as financial or investment advice. Engaging in stock market activities involves inherent risks, and outcomes can be unpredictable. While we strive to provide accurate and up-to-date information, we do not make any guarantees regarding the completeness or reliability of the content. Any investment decisions you make should be based on your own research and consultation with a qualified financial professional. We are not responsible for any financial gains or losses resulting from actions taken based on the information provided here. Always invest wisely and at your own risk.
